X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Insider Mark Baldry Sells 29,159 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) insider Mark Baldry sold 29,159 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $13,121.55. Following the completion of the sale, the insider now directly owns 94,123 shares in the company, valued at approximately $42,355.35. This represents a 23.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $0.48 on Wednesday. The firm has a market cap of $82.17 million, a P/E ratio of -5.35 and a beta of 0.14. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The company’s 50 day moving average is $0.55 and its 200-day moving average is $0.61. X4 Pharmaceuticals, Inc. has a 12-month low of $0.26 and a 12-month high of $1.60.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of X4 Pharmaceuticals in the third quarter worth $340,000. AQR Capital Management LLC lifted its holdings in X4 Pharmaceuticals by 1,080.3% during the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares in the last quarter. State Street Corp boosted its stake in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after purchasing an additional 189,105 shares during the period. Barclays PLC grew its holdings in X4 Pharmaceuticals by 196.0% during the 3rd quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after buying an additional 183,861 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of X4 Pharmaceuticals by 233.0% during the fourth quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock valued at $134,000 after buying an additional 128,148 shares during the period. Institutional investors own 72.03% of the company’s stock.

Analyst Upgrades and Downgrades

XFOR has been the topic of a number of research reports. Stifel Nicolaus lowered their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.